[go: up one dir, main page]

WO2025013019A1 - Formulation d'agent hémostatique - Google Patents

Formulation d'agent hémostatique Download PDF

Info

Publication number
WO2025013019A1
WO2025013019A1 PCT/IN2024/051067 IN2024051067W WO2025013019A1 WO 2025013019 A1 WO2025013019 A1 WO 2025013019A1 IN 2024051067 W IN2024051067 W IN 2024051067W WO 2025013019 A1 WO2025013019 A1 WO 2025013019A1
Authority
WO
WIPO (PCT)
Prior art keywords
hemostatic
hemostatic agent
formulation
range
fabric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IN2024/051067
Other languages
English (en)
Inventor
Kapil Bhimani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2025013019A1 publication Critical patent/WO2025013019A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the present invention relates to the field of haemostatic formulations and, more particularly, to a novel haemostatic formulation for the control of bleeding with two potential applications, one is spray formulation and another is integration with fabric that can be further used in armor.
  • haemorrhage control is of paramount importance. Uncontrolled bleeding can rapidly lead to shock, organ failure, and, if left untreated, death may cause. Effective haemostatic materials and techniques are, therefore, essential to addressing this critical aspect of trauma care.
  • Speed of action is also a critical factor, as many haemostatic materials rely on natural clotting processes that may be too slow in emergencies. Furthermore, cost can be a significant barrier, with advanced haemostatic products often being expensive and inaccessible in low-resource settings.
  • An invention disclosed in patent application number US9265858B2 discloses a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures.
  • the paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form.
  • Further disclosed are methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes.
  • haemostatic compositions comprising components of the flowers of pharmaceutical chamomile (Chamomilla recutita), the leaves of dioecious nettle (Urtica dioica), kaolin, chitosan, fibrinogen and thrombin. Further inclusion of a biocompatible polymeric base, particularly an alignate, generates a composition with superior and broad-spectrum haemostatic capabilities, including the ability to arrest arterial haemorrhage.
  • the invention further provides methods of using the inventive compositions in to reduce or stop bleeding, as well as a variety of apparatuses useful in haemostatic contexts that incorporate the inventive compositions.
  • the invention provides haemostatic dressings in which a polymeric layer incorporating chamomile, nettle, kaolin, chitosan, fibrinogen and thrombin components is applied to a textile or fabric material, for example a non-woven viscose.
  • Certain haemostatic agents have also been associated with adverse reactions, including inflammation and tissue damage, which can hinder the healing process.
  • the present invention offers a technological solution to address these limitations by introducing a novel haemostatic formulation. This formulation is designed to be highly effective, acting rapidly to control bleeding, and easy to use, ensuring efficiency in emergency situations. Additionally, making it accessible to a wider range of medical settings.
  • the present invention introduces a technological approach to control bleeding with a novel hemostatic formulation delivered through a unique spray format and integration with fabric to be further used in Armor.
  • the present novel invention intersects with three critical domains in medical advancement: hemostatic agents, drug delivery systems, and wound management practices, offering a comprehensive solution for hemorrhage control.
  • present invention introduces a novel spraybased formulation that sets itself apart from traditional methods.
  • the spray format provides a practical and efficient way to manage bleeding, making it a quick and easy solution for trauma care.
  • One of the key advantages of our invention is its specialized drug delivery system. This system is meticulously designed for the hemostatic formulation, ensuring precise and targeted application. By optimizing the delivery mechanism, the effectiveness of the hemostatic agent is maximized, leading to swift and controlled bleeding management.
  • the invention significantly contributes to wound management practices.
  • the novel formulation is versatile and effective for various wound types, providing a much-needed solution in emergency situations. Whether it's a deep laceration or a broad abrasion, the spray-based format offers a convenient and efficient way to manage bleeding, improving patient outcomes.
  • this novel hemostatic formulation is its integration into fabrics to create advanced armor. By infusing the formulation into the fabric fibers, any lacerations sustained by the wearer will immediately be treated, reducing blood loss and increasing the chances of recovery.
  • the invention's uniqueness lies in its ability to synergistically combine these three subfields.
  • Principal objective of the present novel invention is to provide a novel hemostatic formulation with two distinct and innovative applications, offering a rapid and effective solution for hemorrhage control in emergency situations.
  • Another objective of the present novel invention is to provide a formulation that design to act swiftly upon contact with the wound, initiating rapid clotting and sealing the injury to prevent further blood loss.
  • Another objective of the present novel invention is to provide versatility as it aims to be adaptable to various traumatic injury scenarios, whether external or internal bleeding, the spray-based delivery system can reach and treat different wound types, ensuring versatility and broad applicability.
  • Another objective of the present novel invention is to provide a formulation that is biocompatible and non-toxic.
  • Another objective of the present novel invention is to provide a highly effective, safe, and accessible solution as it strives to become a go-to tool in emergency medicine, improving patient outcomes and saving lives worldwide.
  • the present invention introduces a ground-breaking novel hemostatic formulation with two distinct and innovative applications, offering a comprehensive approach to hemorrhage control and wound management. Firstly, it revolutionizes the field of hemostatic agents with a unique spray-based delivery method, providing a practical and efficient solution. This specialized spray delivery system ensures precise and targeted application, enhancing the effectiveness of the hemostatic agent.
  • the invention intersects three critical subfields: hemostatic agents, drug delivery systems, and wound management, offering a synergistic approach to trauma care.
  • One of the key applications of the present novel formulation is its use as a hemostatic spray, providing a convenient and portable solution for emergency situations.
  • the spray format allows for easy and rapid application, making it ideal for first responders, military personnel, and trauma care settings.
  • the hemostatic agent can be swiftly applied to control bleeding and improve patient outcomes.
  • the invention showcases its versatility with the integration of the hemostatic agent into fabric used in armor.
  • the formulation By infusing the formulation into the fabric, it provides continuous hemostatic protection to potential wound areas.
  • This application ensures that any lacerations or injuries sustained are immediately treated, reducing blood loss and enhancing the chances of recovery.
  • the treatment of the fabric can be done through controlled methods such as spraying, dip coating, or weaving, ensuring even coverage and effectiveness.
  • Glycerin (4) Humectant and skin-hydrating agent.
  • Hydroxypropyl cellulose (5) Thickening and binding agent.
  • Ethyl Cellulose (7) Thickening agent and film-forming agent.
  • Colloidal Silicon Dioxide (8) act as a glidant, flow agent, and adsorbent.
  • the mixture optionally pass through a sterile filter to eliminate potential contaminants or undispersed particles.
  • the hemostatic agent can be filled into compatible spray containers designed for LPG propellant.
  • the LPG gas and the novel hemostatic formulation should be mixed in a 1:1 ratio.
  • the hemostatic agent can be incorporated into the fabric used in armor to provide hemostatic protection.
  • the first layer made of cotton, is in direct contact with the body, absorbing sweat and providing a comfortable and soft feel.
  • the second layer a clever combination of synthetic material and a novel powder/crystal composition, is designed with gaps filled with cotton.
  • This dual-layer system ensures that while the cotton layer absorbs sweat, it does not penetrate the synthetic layer, keeping the novel powder composition safe and dry even during perspiration.
  • This innovative design is fixable and strategically covers areas like the chest, back, neck, shoulders, and thighs, providing targeted protection and comfort.
  • the present novel hemostatic agent can be formulated, and its applications can be tailored for specific purposes, such as a convenient spray formulation or integration with fabric in armor for continuous protection.
  • the versatility of the formulation allows for a range of potential uses, all contributing to effective wound management and improved outcomes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une nouvelle formulation d'agent hémostatique confectionnée de manière méticuleuse pour deux applications distinctes : une pulvérisation hémostatique pratique et une intégration avec un tissu de blindage protecteur. Le procédé de préparation implique la combinaison soignée d'ingrédients clés, comprenant du polyacrylamide de sodium (1), de la vitamine K2 (12), du propylèneglycol (3), du glycérol (4) et de l'éthanol (2) en tant que solvant primaire. De l'éthylcellulose (7) et de l'hydroxypropylcellulose (5) sont ajoutées pour la stabilité et la régulation de la viscosité, tandis que la polyvinylpyrrolidone (PVP) (6) améliore la liaison. Du dioxyde de silicium colloïdal (8), du talc (9), du stéarate de magnésium (10) et de l'alun (11) sont inclus pour leurs propriétés absorbantes. La formulation est optimisée pour la consistance et la dispersion, avec un ajustement du pH selon les besoins. L'agent hémostatique est ensuite utilisé pour des récipients de pulvérisation avec un agent propulseur GPL ou intégré dans un tissu de blindage par l'intermédiaire de procédés d'application régulés, offrant une protection hémostatique pour des plaies. Cette formulation polyvalente met en évidence le potentiel d'interventions personnalisées dans le traitement des plaies d'urgence, offrant une solution de sauvetage avec une efficacité accrue et de meilleurs résultats pour les patients.
PCT/IN2024/051067 2023-07-07 2024-07-05 Formulation d'agent hémostatique Pending WO2025013019A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202321045879 2023-07-07
IN202321045879 2023-07-07

Publications (1)

Publication Number Publication Date
WO2025013019A1 true WO2025013019A1 (fr) 2025-01-16

Family

ID=94215014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2024/051067 Pending WO2025013019A1 (fr) 2023-07-07 2024-07-05 Formulation d'agent hémostatique

Country Status (1)

Country Link
WO (1) WO2025013019A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120993A1 (en) * 2002-12-20 2004-06-24 Guanghui Zhang Hemostatic wound dressing and fabric and methods of making and using same
WO2008100977A2 (fr) * 2007-02-14 2008-08-21 N.V. Organon Agents de libération thérapeutiques
CN107582750A (zh) * 2017-09-22 2018-01-16 高军 一种治疗皮肤病的外用中药组合物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040120993A1 (en) * 2002-12-20 2004-06-24 Guanghui Zhang Hemostatic wound dressing and fabric and methods of making and using same
WO2008100977A2 (fr) * 2007-02-14 2008-08-21 N.V. Organon Agents de libération thérapeutiques
CN107582750A (zh) * 2017-09-22 2018-01-16 高军 一种治疗皮肤病的外用中药组合物及其制备方法

Similar Documents

Publication Publication Date Title
EP3659631B1 (fr) Pansement comprenant de l'acide hyaluronique-calcium et de la polylysine et procédé de fabrication s'y rapportant
US6568398B2 (en) Method for hemostasis
US10493094B2 (en) Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
EP2200690B1 (fr) Système pour appliquer un film de protection cutanée ayant un composant d'indication visuelle de changement de phase
CN102133421B (zh) 一种快速止血创伤敷料及其制备方法与应用
US7981872B2 (en) Hemostatic material
WO2009047655A2 (fr) Composition d'indication visuelle de changement de phase
WO2008032231A2 (fr) Film de protection cutanée à changement de couleur
Chaturvedi et al. Hydrophobically modified chitosan gauze: a novel topical hemostat
WO2008153714A1 (fr) Compositions minérales hémostatiques et utilisations de celles-ci
Geng et al. Convergent architecting of multifunction-in-one hydrogels as wound dressings for surgical anti-infections
RU2249467C2 (ru) Медицинский материал и изделия на его основе
JP2014501260A (ja) ゴールデン・モスの抽出物を含んだ止血製剤
WO2025013019A1 (fr) Formulation d'agent hémostatique
KR102615766B1 (ko) 키토산 및 젤라틴을 포함하는 조직 보강용 점착 조성물 및 이의 제조방법
EP3169379B1 (fr) Matière cellulosique de mélange et son procédé de fabrication et d'utilisation
CN107412840A (zh) 一种具有稳定药效的止血组合物
Sarkar et al. Antibacterial sponge for rapid noncompressible hemostatic treatment: spatiotemporal studies using a noninvasive model
RU2242987C1 (ru) Гемостатическое средство
JP2010513291A (ja) 血液の凝固を加速させる無機固形物
RU2133115C1 (ru) Перцовый пластырь
EP2970731B1 (fr) Pâte polymère biocompatible fonctionnelle avancée utilisée comme agent hémostatique pour le traitement de tissu et de cellules endommagés
Narayan Hydrophobically Modified Chitosan Gauze for Control of Massive Hemorrhage
CN117298321A (zh) 一种医用皮肤护理敷料及其制备方法
Wiśniewska-Wrona et al. Study on the usability of polymer complexes in the form of films applied in bedsore treatments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24839132

Country of ref document: EP

Kind code of ref document: A1